Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 3/20 | 0.62 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.61 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | TMPRSS4 | Q9NRS4 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | IL2 | P60568 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16363171 | 0.87 | LMNA (0.61) | P2RX1P2RX4P2RX7TMPRSS4LMNA | |
| SCHEMBL8297621 | 0.87 | RXFP1 (0.57) | P2RX1TRPV1LMNASMN1; SMN2PTGS1 | |
| SCHEMBL1826042 | 0.84 | RXFP1 (0.59) | SMN1; SMN2TP53RAB9AMAPTAVPR2 | |
| SCHEMBL1825927 | 0.84 | IL2 (0.59) | P2RX1P2RX7TRPV1SMN1; SMN2PTGS1 | |
| SCHEMBL2698258 | 0.83 | P2RX1 (0.75) | P2RX1P2RX4P2RX7TMPRSS4LMNA | |
| SCHEMBL30665186 | 0.83 | P2RX1 (0.75) | P2RX1P2RX4P2RX7TMPRSS4LMNA | |
| SCHEMBL1827094 | 0.83 | IL2 (0.50) | P2RX1TRPV1SMN1; SMN2PTGS1IL2 | |
| SCHEMBL1825397 | 0.82 | IL2 (0.57) | P2RX1P2RX7TRPV1SMN1; SMN2PTGS1 | |
| SCHEMBL1828980 | 0.81 | TRPV1 (0.57) | TRPV1 | |
| SCHEMBL1826148 | 0.81 | IL2 (0.56) | P2RX1P2RX4P2RX7TRPV1TMPRSS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651232-B1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2010-12-22 | — | — | EP | claimed |
| EP-1651232-A4 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2007-06-06 | — | — | EP | claimed |
| EP-1653968-A4 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | SYNTA PHARMACEUTICALS CORP (US) | 2006-09-06 | — | — | EP | claimed |
| EP-1653968-A2 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | Synta Pharmaceuticals Corporation (US) | 2006-05-10 | — | — | EP | claimed |
| EP-1651232-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2006-05-03 | — | — | EP | claimed |
| US-20050148633-A1 | Calcium channel blockers and releasing ions for prodrugs | SYNTA PHARMACEUTICALS CORP. | 2005-07-07 | — | — | US | claimed |
| US-20050107436-A1 | phenyl and pyridyl derivatives such as 3-Fluoro-N-(2'-trifluoromethyl-biphenyl-4-yl)-isonicotinamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. | 2005-05-19 | — | — | US | claimed |
| WO-2005009954-A2 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | claimed |
| WO-2005009539-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | claimed |
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140107134-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-17 | — | — | US | disclosed |
| EP-2319516-A1 | Compounds for treating inflammatory and autoimmune disorders | Synta Pharmaceuticals Corp. (US) | 2011-05-11 | — | — | EP | disclosed |
| EP-2319516-A1 | Compounds for treating inflammatory and autoimmune disorders | Synta Pharmaceuticals Corp. (US) | 2011-05-11 | — | — | EP | disclosed |
| EP-1651232-B1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2010-12-22 | — | — | EP | disclosed |
| US-20050148633-A1 | Calcium channel blockers and releasing ions for prodrugs | SYNTA PHARMACEUTICALS CORP. | 2005-07-07 | — | — | US | disclosed |
| US-20050107436-A1 | phenyl and pyridyl derivatives such as 3-Fluoro-N-(2'-trifluoromethyl-biphenyl-4-yl)-isonicotinamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. | 2005-05-19 | — | — | US | disclosed |
| WO-2005009954-A2 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009954-A2 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009539-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009539-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107134-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | P2RX1 460/4885P2RX4 754/4885P2RX7 211/4885 |
| US-20050148633-A1 | Calcium channel blockers and releasing ions for prodrugs | ORAI1, CACNA1C, CACNA1F | P2RX1 149/4885P2RX4 194/4885P2RX7 203/4885 |
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | P2RX1 460/4885P2RX4 754/4885P2RX7 211/4885 |
| US-20050107436-A1 | phenyl and pyridyl derivatives such as 3-Fluoro-N-(2'-trifluoromethyl-biphenyl-4-yl)-isonicotinamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | TPMT, PTPN3, FKBP3 | P2RX1 897/4885P2RX4 986/4885P2RX7 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.